UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE by Alistair J. Roddick, Alexa Wonnacott, David Webb, Angela Watt, Michael A. Watson, Natalie Staplin, Alex Riding, Eirini Lioudaki, Apexa Kuverji, Mohsen El Kossi, Patrick Holmes, Matt Holloway, Donald Fraser, Chris Carvalho, James O. Burton, Sunil Bhandari, William G. Herrington, Andrew H. Frankel

Subjects: Get full text

SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier by Inês Aguiar-Neves, Diogo Santos-Ferreira, Ricardo Fontes-Carvalho

Subjects: Get full text

Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease by Riccardo Nevola, Maria Alfano, Pia Clara Pafundi, Chiara Brin, Felice Gragnano, Paolo Calabrò, Luigi Elio Adinolfi, Luca Rinaldi, Ferdinando Carlo Sasso, Alfredo Caturano

Subjects: Get full text

Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies by Andre J. Scheen

Subjects: Get full text

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk by André J. Scheen

Subjects: Get full text

TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY? by Zh. D. Kobalava, G. К. Kiyakbaev

Subjects: Get full text

Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review by Mina Gholami, Natalie Coleman-Fuller, Mahsa Salehirad, Sepideh Darbeheshti, Majid Motaghinejad

Subjects: Get full text

Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series by Pusem Patır, Kübra Çerçi, Erdal Kurtoğlu

Subjects: Get full text

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans by Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam, Nancy Antoine, Firas Khattab, Bao-Khanh Lai, Davide Brusa, Birgit Stierstorfer, Holger Klein, Bilal Singh, Lucie Ruiz, Michael Pieper, Michael Mark, Pedro L. Herrera, Fiona M. Gribble, Frank Reimann, Anne Wojtusciszyn, Christophe Broca, Nano Rita, Lorenzo Piemonti, Patrick Gilon

Subjects: “…Gliflozins…”
Get full text

Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials by Arjun K. Pandey, Iva Okaj, Hargun Kaur, Emilie P. Belley‐Cote, Jia Wang, Alireza Oraii, Alexander P. Benz, Linda S. B. Johnson, Jack Young, Jorge A. Wong, Subodh Verma, David Conen, Hertzel Gerstein, Jeff S. Healey, William F. McIntyre

Subjects: Get full text

Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function by Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, Anna Di Martino, Gaetana Albanese, Erica Vetrano, Celestino Sardu, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso

Subjects: Get full text

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation by D. A. Ishmaev, M. S. Vasileva, D. V. Duplyakov

Subjects: Get full text

Standardized Chromatographic and Computational Approaches for Lipophilicity Analysis of Five Gliflozin Antidiabetic Drugs in Relation to Their Biological Activity by Anna Gumieniczek, Anna Berecka-Rycerz, Marcelina Dul, Aleksandra Pryjda

Subjects: “…gliflozins…”
Get full text

NASH: A glance at the landscape of pharmacological treatment by Lucia Brodosi, Francesca Marchignoli, Maria Letizia Petroni, Giulio Marchesini

Subjects: Get full text

The Sodium–Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study by Pasquale Pignatelli, Francesco Baratta, Raffaella Buzzetti, Alessandra D’Amico, Valentina Castellani, Simona Bartimoccia, Antonio Siena, Luca D’Onofrio, Ernesto Maddaloni, Annachiara Pingitore, Giovanni Alfonso Chiariello, Francesca Santilli, Daniele Pastori, Nicholas Cocomello, Francesco Violi, Maria Del Ben, Vittoria Cammisotto, Roberto Carnevale

Subjects: “…gliflozins…”
Get full text

Is cancer incidence modified by SGLT2 inhibitors? by Lev M. Berstein

Subjects: Get full text

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia by Cheng-Hsien Hung, Li-Yu Lu

Subjects: Get full text

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful? by Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, Stanisław Surma, Krzysztof J. Filipiak, Aleksandra Gąsecka

Subjects: “…SGLT-2 inhibitors (gliflozins)…”
Get full text

Is REmogliflozin an effective Drug in MANaging Type-2 diabetes mellitus: A comparative study – (REDMAN) by Prabhat Agrawal, Nikhil Pursnani, Ashish Gautam, Ruchika Garg

Subjects: Get full text

Promising areas of pharmacotherapy for obesity by M. A. Druzhilov, T. Yu. Kuznetsova, G. A. Chumakova

Subjects: Get full text